Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Viridian Therapeutics, Inc.
VRDN
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.7B
$18.99
▲ +2.78%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$13.18 - $34.29
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 21.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Focused pipeline targeting IGF-1R pathway with validated mechanism of action in TED
- Humanized monoclonal antibody platform enabling potentially improved safety and efficacy profiles
- First-mover advantage in IGF-1R antibody development for thyroid eye disease indication
Bear Case
2 risks
- Average volatility.
- Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Growth
Moderate growth ahead
Clinical trial progression of VRDN-001 with potential for breakthrough therapy designation in TED
Value
Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Momentum
Stable
-1.9% over 3m
Quality
Excellent
High-growth business (500% revenue growth, 99% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying VRDN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 4, 2026
MAY 5, 2026
Reported EPS of -$0.90 vs -$1.06 consensus (+15.1% surprise). Revenue of $141.0K vs $36.1K expected (+290.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+15.1%
Next: May 4, 2026
Revenue trend · last 8Q
—
—
0%
0%
+4%
+81958%
+83%
+96%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$72.0K
$86.0K
$72.0K
$72.0K
$75.0K
$70.6M
$132.0K
$141.0K
Margins · last 8Q
Gross
—
Operating
—
Profit
-74397.9%
Wall Street consensus
9 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$34.00
▲ +79.0% vs $18.99
Latest: RBC Capital · Jun 30, 2026
6 analysts covering